Hepatocellular carcinoma (HCC) is a type of liver cancer that is often difficult to treat, and has a high mortality rate. Targeted drug therapies are a promising approach to treating HCC, as they specifically target the molecular pathways that contribute to the development and progression of this cancer.
Targeted drug therapies for Hepatocellular Carcinoma Drugs include tyrosine kinase inhibitors, such as sorafenib, regorafenib, and lenvatinib, which block specific enzymes involved in tumor growth and blood vessel formation. Other targeted therapies include monoclonal antibodies, such as ramucirumab, which inhibit angiogenesis, and immune checkpoint inhibitors, such as nivolumab and pembrolizumab, which activate the immune system to target cancer cells. While targeted drug therapies have shown promise in HCC treatment, challenges remain, including drug resistance and toxicity. Therefore, ongoing research is needed to identify novel targeted therapies, as well as combination therapies that may improve treatment outcomes.
Read More:
Sign in to leave a comment.